Abstract
During 2009, multiple major cardiology trials have been presented or published. In this paper, we summarize and place in clinical context the new trial findings regarding anticoagulation (dabigatran), antiplatelet therapy (ticagrelor, clopidogrel, prasugrel and aspirin), percutaneous coronary management (thrombectomy, multivessel/left main disease and biodegradable polymers), medical therapy for coronary disease (ivabradine and rosuvastatin) and management of heart failure (beta-blocker strategy, atrial fibrillation and resynchronization therapy).
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angioplasty, Balloon, Coronary / trends
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use
-
Aspirin / therapeutic use
-
Cardiac Pacing, Artificial
-
Cardiology / trends*
-
Coronary Artery Disease / drug therapy*
-
Coronary Artery Disease / surgery
-
Coronary Artery Disease / therapy
-
Drug-Eluting Stents
-
Evidence-Based Medicine
-
Heart Failure / drug therapy*
-
Heart Failure / surgery
-
Heart Failure / therapy
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Platelet Aggregation Inhibitors / therapeutic use
Substances
-
Adrenergic beta-Antagonists
-
Anticoagulants
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Platelet Aggregation Inhibitors
-
Aspirin